RU2019115392A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019115392A3 RU2019115392A3 RU2019115392A RU2019115392A RU2019115392A3 RU 2019115392 A3 RU2019115392 A3 RU 2019115392A3 RU 2019115392 A RU2019115392 A RU 2019115392A RU 2019115392 A RU2019115392 A RU 2019115392A RU 2019115392 A3 RU2019115392 A3 RU 2019115392A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437400P | 2016-12-21 | 2016-12-21 | |
| US62/437,400 | 2016-12-21 | ||
| US201762485563P | 2017-04-14 | 2017-04-14 | |
| US62/485,563 | 2017-04-14 | ||
| US201762538203P | 2017-07-28 | 2017-07-28 | |
| US62/538,203 | 2017-07-28 | ||
| PCT/US2017/067353 WO2018118947A1 (en) | 2016-12-21 | 2017-12-19 | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019115392A RU2019115392A (ru) | 2021-01-22 |
| RU2019115392A3 true RU2019115392A3 (ru) | 2021-05-14 |
| RU2771166C2 RU2771166C2 (ru) | 2022-04-27 |
Family
ID=60991575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019115392A RU2771166C2 (ru) | 2016-12-21 | 2017-12-19 | Производные тиенопиррола для применения для нацеливания на белки, композиции с указанными производными, способы и применения |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10040804B2 (ru) |
| EP (1) | EP3559005A1 (ru) |
| JP (1) | JP2020504711A (ru) |
| KR (1) | KR20190093205A (ru) |
| CN (1) | CN110099907A (ru) |
| AU (1) | AU2017382176A1 (ru) |
| CA (1) | CA3043938A1 (ru) |
| IL (1) | IL267323A (ru) |
| MX (1) | MX2019007434A (ru) |
| RU (1) | RU2771166C2 (ru) |
| TW (2) | TW201835089A (ru) |
| WO (1) | WO2018118947A1 (ru) |
| ZA (1) | ZA201903479B (ru) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CA3043938A1 (en) | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| JP2021519786A (ja) * | 2018-03-30 | 2021-08-12 | バイオセリックス， インコーポレイテッド | チエノピリミジノン化合物 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| JP7365059B2 (ja) * | 2018-06-13 | 2023-10-19 | バイオセリックス， インコーポレイテッド | 縮合チオフェン化合物 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| US12065442B2 (en) | 2018-08-22 | 2024-08-20 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| FR3092581A1 (fr) * | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
| KR20220023343A (ko) | 2019-05-24 | 2022-03-02 | 바이오테릭스, 인코포레이티드 | 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용 |
| KR20220103753A (ko) | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| AU2020405237A1 (en) | 2019-12-20 | 2022-07-07 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of EGFR |
| IL295101A (en) | 2020-01-29 | 2022-09-01 | Foghorn Therapeutics Inc | materials and their use |
| BR112022017393A2 (pt) | 2020-03-05 | 2022-10-18 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022073469A1 (en) * | 2020-10-07 | 2022-04-14 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022132603A1 (en) | 2020-12-14 | 2022-06-23 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| BR112023020077A2 (pt) | 2021-04-06 | 2023-11-14 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituída por piridinila |
| MX2023013173A (es) | 2021-05-07 | 2023-11-30 | Kymera Therapeutics Inc | Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. |
| WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| US20240158370A1 (en) * | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585377A (en) | 1990-04-09 | 1996-12-17 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| DE4023048A1 (de) | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| ES2118941T3 (es) | 1992-02-21 | 1998-10-01 | Alcon Lab Inc | Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta. |
| US5420923A (en) | 1993-02-16 | 1995-05-30 | Scientific-Atlanta, Inc. | Addressed messaging in a cable television system |
| US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| WO1995033746A1 (en) | 1994-06-08 | 1995-12-14 | E.I. Du Pont De Nemours And Company | Cyclic sulfonamide herbicides |
| WO1996011201A1 (en) | 1994-10-11 | 1996-04-18 | Takeda Chemical Industries, Ltd. | Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors |
| ATE239468T1 (de) | 1996-02-26 | 2003-05-15 | Advanced Res & Tech Inst | Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| JPH10264532A (ja) | 1997-03-24 | 1998-10-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| US6906245B1 (en) | 1998-04-30 | 2005-06-14 | Sumitomo Chemical Company, Limited | Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants |
| AU753020B2 (en) | 1998-04-30 | 2002-10-03 | Sumitomo Chemical Company, Limited | Method for giving resistance to weed control compounds to plants |
| JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| JP4821038B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| JP4821036B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| JP2004018434A (ja) | 2002-06-14 | 2004-01-22 | Mitsui Chemicals Inc | 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子 |
| US7247736B2 (en) | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
| WO2004056797A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| CA2588389A1 (en) | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting vegf production |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2661842C (en) | 2006-09-01 | 2017-08-22 | Cylene Pharmaceuticals, Inc. | Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| JP2008273924A (ja) | 2007-03-30 | 2008-11-13 | Meiji Seika Kaisha Ltd | ２位チエニルカルバペネム誘導体 |
| KR101128943B1 (ko) | 2007-04-13 | 2012-03-27 | 주식회사 엘지화학 | 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자 |
| WO2010042674A1 (en) | 2008-10-08 | 2010-04-15 | Bristol-Myers Squibb Company | Pyrrolone melanin concentrating hormone receptor-1 antagonists |
| US20120028985A1 (en) | 2008-11-07 | 2012-02-02 | 4Sc Ag | Combinational therapy for treating autoimmune disease |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| KR20180031823A (ko) | 2010-09-01 | 2018-03-28 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
| US20120085992A1 (en) | 2010-09-30 | 2012-04-12 | The Regents Of The University Of California | Furan Conjugated Polymers Useful for Photovoltaic Applications |
| EP2652004A2 (en) | 2010-12-15 | 2013-10-23 | Plextronics, Inc. | Fluoro monomers, oligomers, and polymers for inks and organic electronic devices |
| EP2697236A1 (en) | 2011-04-15 | 2014-02-19 | Georgia Tech Research Corporation | Stannyl derivatives of naphthalene diimides and related compositions and methods |
| ITMI20110881A1 (it) | 2011-05-18 | 2012-11-19 | E T C Srl | Materiale semiconduttore organico |
| WO2013052153A1 (en) | 2011-10-05 | 2013-04-11 | Georgia Tech Research Corporation | Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices |
| JP2014047196A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子 |
| JP2014047192A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子 |
| CN103664916B (zh) | 2012-09-12 | 2016-08-24 | 中国科学院化学研究所 | 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用 |
| ITMI20121691A1 (it) | 2012-10-09 | 2014-04-10 | E T C Srl | Materiale semiconduttore organico |
| ITMI20121939A1 (it) | 2012-11-15 | 2014-05-16 | E T C Srl | Materiale organico semiconduttore |
| ITMI20121952A1 (it) | 2012-11-16 | 2014-05-17 | E T C Srl | Materiale semiconduttore organico |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| JP2014185147A (ja) | 2013-02-22 | 2014-10-02 | Mitsubishi Chemicals Corp | イミド縮合環化合物及びイミド縮合環化合物の製造方法 |
| JP6248400B2 (ja) | 2013-03-15 | 2017-12-20 | 株式会社リコー | 感光体及び画像形成装置 |
| JP2015013989A (ja) | 2013-06-05 | 2015-01-22 | 三菱化学株式会社 | コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール |
| WO2014204082A1 (ko) | 2013-06-20 | 2014-12-24 | 경상대학교산학협력단 | 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지 |
| KR101595919B1 (ko) | 2013-08-30 | 2016-02-29 | 한국과학기술연구원 | 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지 |
| US9809594B2 (en) | 2013-09-10 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Non-fullerene electron acceptors for organic photovoltaic devices |
| KR101732220B1 (ko) | 2014-03-31 | 2017-05-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 태양 전지 |
| CN105294536B (zh) | 2014-06-30 | 2018-06-29 | 中国科学院上海有机化学研究所 | 一种制备3-亚氨基异吲哚啉酮类化合物的方法 |
| EP3182996B1 (en) * | 2014-08-22 | 2022-12-28 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| CN104230953B (zh) | 2014-08-25 | 2016-08-17 | 中国科学院上海有机化学研究所 | 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物 |
| WO2016061751A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| CN105693745B (zh) | 2014-11-27 | 2019-07-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 有机π-共轭化合物、其制备方法及应用 |
| NZ737355A (en) | 2015-05-22 | 2019-05-31 | Biotheryx Inc | Compounds targeting proteins, compositions, methods, and uses thereof |
| CA3043938A1 (en) * | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
-
2017
- 2017-12-19 CA CA3043938A patent/CA3043938A1/en not_active Abandoned
- 2017-12-19 CN CN201780079826.3A patent/CN110099907A/zh active Pending
- 2017-12-19 MX MX2019007434A patent/MX2019007434A/es unknown
- 2017-12-19 US US15/847,628 patent/US10040804B2/en active Active
- 2017-12-19 WO PCT/US2017/067353 patent/WO2018118947A1/en unknown
- 2017-12-19 KR KR1020197018882A patent/KR20190093205A/ko not_active Application Discontinuation
- 2017-12-19 JP JP2019526486A patent/JP2020504711A/ja active Pending
- 2017-12-19 AU AU2017382176A patent/AU2017382176A1/en not_active Abandoned
- 2017-12-19 EP EP17829823.8A patent/EP3559005A1/en not_active Withdrawn
- 2017-12-19 RU RU2019115392A patent/RU2771166C2/ru active
- 2017-12-21 TW TW106145115A patent/TW201835089A/zh unknown
- 2017-12-21 TW TW109142439A patent/TWI756957B/zh not_active IP Right Cessation
-
2018
- 2018-06-18 US US16/011,090 patent/US10336771B2/en active Active
-
2019
- 2019-05-30 ZA ZA2019/03479A patent/ZA201903479B/en unknown
- 2019-06-13 IL IL267323A patent/IL267323A/en unknown
- 2019-06-28 US US16/457,409 patent/US10889593B2/en active Active
-
2021
- 2021-01-11 US US17/146,479 patent/US11345714B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11345714B2 (en) | 2022-05-31 |
| MX2019007434A (es) | 2019-08-16 |
| TW202120514A (zh) | 2021-06-01 |
| IL267323A (en) | 2019-08-29 |
| TW201835089A (zh) | 2018-10-01 |
| KR20190093205A (ko) | 2019-08-08 |
| AU2017382176A1 (en) | 2019-05-30 |
| CA3043938A1 (en) | 2018-06-28 |
| CN110099907A (zh) | 2019-08-06 |
| JP2020504711A (ja) | 2020-02-13 |
| US10040804B2 (en) | 2018-08-07 |
| US20180298027A1 (en) | 2018-10-18 |
| US10889593B2 (en) | 2021-01-12 |
| US20210139500A1 (en) | 2021-05-13 |
| US20190322683A1 (en) | 2019-10-24 |
| TWI756957B (zh) | 2022-03-01 |
| US10336771B2 (en) | 2019-07-02 |
| WO2018118947A1 (en) | 2018-06-28 |
| US20180170948A1 (en) | 2018-06-21 |
| RU2771166C2 (ru) | 2022-04-27 |
| ZA201903479B (en) | 2021-09-29 |
| EP3559005A1 (en) | 2019-10-30 |
| RU2019115392A (ru) | 2021-01-22 |